RCS - Oxford BioDynamics - OBD and King's College London collaborate on RA

Oxford BiodynamicsAnnouncement

16/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240516:nRSP6309Oa&default-theme=true

RNS Number : 6309O  Oxford BioDynamics PLC  16 May 2024

 

 

Oxford BioDynamics and King's College London collaborate to develop
EpiSwitch® prognostic and predictive biomarkers for best prevention of
rheumatoid arthritis following the APIPPRA trial.

·  APIPPRA trial is the largest rheumatoid arthritis (RA) prevention trial
to date, led by Professor Andy Cope, King's College London

·  Data published in The Lancet in February 2024, showed that 92.8% of
patients at risk of RA, when treated with Abatacept, remained RA-free at the
end of the one year of treatment

·   25% of treated patients who initially showed response subsequently
developed RA

·  Highlights the need for improved stratification tools to identify
individuals at high risk of RA, with  predicted efficacious response to
Abatacept

·   Professor Cope and his team at King's College London, are now
collaborating with Oxford BioDynamics, to develop prognostic and predictive
blood-based EpiSwitch® biomarkers to identify patients at risk of RA who can
benefit from Abatacept treatment

 

Oxford, UK - 16 May 2024 - Oxford BioDynamics, Plc (AIM: OBD, "OBD" or the
"Company" and, together with its subsidiaries, the "Group"), a biotechnology
company developing precision medicine tests based on the EpiSwitch® 3D
genomics platform, today announced it is collaborating with the King's College
London team in the immediate follow up of  the APIPPRA trial, the largest RA
prevention trial to date.

The APIPPRA trial of Abatacept was a multicentre trial in 213 individuals at
high risk of rheumatoid arthritis. Break-through results of the trial were
recently published in The Lancet in February 2024  1  and covered in the
mainstream media (links here
(https://www.thetimes.co.uk/article/weekly-jab-could-prevent-rheumatoid-arthritis-trial-finds-73s2xc7tf)
and here
(https://www.telegraph.co.uk/news/2024/02/13/rheumatoid-arthritis-prevented-breakthrough-lancet-study/)
). Prof Andrew Cope, who led the research, commented: "The APIPPRA trial is
the largest rheumatoid arthritis prevention trial to date, and the first to
show a treatment effective in preventing the onset of disease in people at
risk."

In the immediate follow-up of the successful trial, The King's College London
team has now engaged  OBD's EpiSwitch® technology, which has already
delivered successful results on prognosis of disease and prediction of
response to treatment  2,3 , to identify which patients are at the highest
risk of progressing to RA and are likely to benefit from the therapeutic
intervention with Abatacept, in both the short and long term.

While 92.8% of those treated with Abtacept were RA-free at the end of year 1,
about 25% of this group ultimately progressed to rheumatoid arthritis by the
end of the second year after stopping treatment. This highlights the
importance of an accurate risk assessment and the need for improved
stratification tools to identify those individuals who will have the benefit
of a durable, efficacious response - a task well-suited to EpiSwitch®
biomarkers developed by OBD.

Professor Andrew Cope, King's College London said: "There are currently no
drugs available that prevent this potentially crippling disease. The initial
results from the APIPPRA trial could be good news for people at risk of
arthritis. We are excited about our collaboration with Oxford Biodynamics and
the early results in helping us identify patients at highest risk and how to
reduce it. EpiSwitch® technology is delivering biomarkers of high biological
relevance."

Rheumatoid arthritis (RA) is a common chronic inflammatory immune-mediated
disease of joints, afflicting more than 500,000 in the UK  4,5  and another
1.5M in the US  6 . If not adequately treated, the condition leads to
destruction of synovial joints and significant disability. RA is costly to
individuals and their families; one third of patients with arthritis stop work
within two years of onset because of the deterioration in quality of life
associated with their disease  7 . In the UK, RA costs are estimated to be in
the region of £5 billion per year through direct costs to the National Health
Service (NHS) and associated healthcare providers and indirect costs
associated with early mortality and loss of productivity  8 .

Abatacept is a biological disease-modifying antirheumatic drug recommended for
the treatment of rheumatoid arthritis.  Abatacept has shown efficacy in the
treatment of active rheumatoid arthritis when used as monotherapy or in
combination with conventional disease-modifying antirheumatic drugs in
patients with an inadequate response to other conventional or biological
disease-modifying antirheumatic drugs  1 .

Dr Alexandre Akoulitchev, CSO at OBD, said: "With fast adoption of EpiSwitch®
3D genomic biomarkers across many fields, our collaboration with Professor
Cope is of particular importance.  The value delivered by our proven
biomarker technology in the field of prognostic and predictive biomarkers in
oncology, should and would be matched by applications in rheumatoid arthritis.
Treatment of autoimmune conditions could greatly benefit from the accuracy and
robustness of blood-based EpiSwitch® readouts. With regards to delivering
benefits to patients and health system economics, there is no time to lose."

 

References

1. Cope AP et al. Abatacept in individuals at high risk of rheumatoid
arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel,
placebo-controlled, phase 2b clinical trial. Lancet. 2024. PMID: 38364839

2. Hunter E et al., Development and Validation of Blood-Based Predictive
Biomarkers for Response to PD-1/PD-L1 Checkpoint Inhibitors: Evidence of a
Universal Systemic Core of 3D Immunogenetic Profiling across Multiple
Oncological Indications. Cancers (Basel). 2023 May 10;15(10):2696. doi:
10.3390/cancers15102696.

3. Carini C et al. Chromosome conformation signatures define predictive
markers of inadequate response to methotrexate in early rheumatoid arthritis.
J Transl Med. 2018 Jan 29;16(1):18. doi: 10.1186/s12967-018-1387-9.

4. Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet. 2010;376:
1094-108.

5. Hochberg MC, Spector TD. Epidemiology of rheumatoid arthritis: update.
Baillieres Clin Rheumatol. 1995;9:619-32.

6. Rheumatoid Arthritis by the Numbers: Facts, Statistics, and You
(healthline.com)
(https://www.healthline.com/health/rheumatoid-arthritis/facts-statistics-infographic#Prevalence)

7. Wolfe F, Hawley DJ. The longterm outcomes of rheumatoid arthritis: Work
disability: a prospective 18 year study of 823 patients. J Rheumatol. 1998;25:
2108-17.

8. Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their
predictors in patients with rheumatoid arthritis: a three-year study of 7,527
patients. Arthritis Rheum. 2003;48:2750-62.

-Ends-

 

 For further details please contact:

 Oxford BioDynamics Plc                   +44 (0)1865 518910

 Jon Burrows, CEO

 Paul Stockdale, CFO
 Shore Capital                            +44 (0)20 7408 4090

 Nominated Adviser and Broker

 Advisory: Stephane Auton / Lucy Bowden

 Broking: Fiona Conroy
 Instinctif Partners                       +44 (0)20 7457 2020

 Melanie Toyne-Sewell / Katie Duffell     OxfordBioDynamics@instinctif.com (mailto:OxfordBioDynamics@instinctif.com)

 

Notes to Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing
personalized healthcare by developing and commercializing precision medicine
tests for life-changing diseases.

Its flagship products are the EpiSwitch® CiRT
(https://url.avanan.click/v2/___https:/www.mycirt.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjphN2EwOmU5ZDc2NmYxZjYxNTk4OGE3YzY3NzkzYWRmODlmMmZmMzBmZmU2ZDZlZmNhMWI0ZmRlYjE3Nzc5N2Q4NmUzZTc6cDpU)
 (Checkpoint Inhibitor Response Test) and EpiSwitch® PSE
(http://www.94percent.com)  (EpiSwitch Prostate Screening test) blood tests.
CiRT is a predictive immune response profile for immuno-oncology (IO)
checkpoint inhibitor treatments, launched in February 2022. PSE is a blood
test that boosts the predictive accuracy of a PSA test from 55% to 94% when
testing the presence or absence of prostate cancer, which has been launched in
the US and UK in September 2023.

In March 2021, the Company launched its first commercial prognostic
test, EpiSwitch® CST
(https://url.avanan.click/v2/___https:/covidseveritytest.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjpmZWY1OmMzOGIyYTk2Yjk1OTgyMDNlMGFkNmQwZGU3ZmNmYzQwMzZmMGIwZDQ5NzA0OTAzNDc0NzY2ZDQyZGZiYjk5YWU6cDpU)
 (Covid Severity Test) and the first commercially available microarray kit
for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch®
Explorer Array Kit
(https://url.avanan.click/v2/___https:/store.oxfordbiodynamics.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjpiMWU2OjMzMTc0NWQ5ZWZhODg0MmY1N2EzZjY2YWRkZDI5YjBkOTRhM2M0ZTZkOGJkNWM2Y2I5MDE4MmQ4M2Y4ZjViMDY6cDpU)
, which is available for purchase by the life science research community.

The Company's product portfolio is based on a proprietary 3D genomic biomarker
platform, EpiSwitch®, which can build molecular diagnostic classifiers for
the prediction of response to therapy, patient prognosis, disease diagnosis
and subtyping, and residual disease monitoring in a wide range of indications.

Oxford BioDynamics has participated in more than 40 partnerships with big
pharma and leading institutions including Pfizer, EMD Serono, Genentech,
Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi
Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker
arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an
expertly curated 3D genome knowledgebase comprising hundreds of millions of
data points from over 15,000 samples in more than 30 human diseases.

OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock
Exchange. It also has a commercial office in Gaithersburg and a clinical
laboratory in Frederick, MD, USA, and a reference laboratory in
Penang, Malaysia.

For more information, please visit the Company's
website, www.oxfordbiodynamics.com
(https://url.avanan.click/v2/___http:/www.oxfordbiodynamics.com___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6Njo3ZjFmOjUxZjRiNmRmMzBiMGI3ZjA2NDJjNjFkZTc2MTM5MThjYjUxZGNiN2ZhNmRhNWRkMjY0MTAwNWY4ODA3ZjE4ZjU6cDpU)
, or follow OBD on Twitter
(https://url.avanan.click/v2/___https:/twitter.com/OxBioDynamics___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjplM2FmOjIwMTI1ZWNlOWJkYjRjZDQ1YjA4YWI2NDc0NWY1OWYzNzg1NTEzYjM0NjIwYTZmNTljNjk0YTQ1YzBkMjg0OTM6cDpU)
(@OxBioDynamics) and LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/oxford-biodynamics___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6Njo2YjgzOjcwMGI3YTM5ODdkMDVmNjA5ZDgxN2FmYWVjYTJkMjIzM2E3NTgzYzM0ZGIzMGIyZDIyYWZlZTVjN2QyZmY4ZGQ6cDpU)
.

 

About EpiSwitch®

The 3D configuration of the genome plays a crucial role in gene regulation. By
mapping this architecture and identifying abnormal configurations, EpiSwitch®
can be used to diagnose patients or determine how individuals might respond to
a disease or treatment.

Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics'
award-winning, proprietary platform that enables screening, evaluation,
validation and monitoring of 3D genomic biomarkers. The technology is fully
developed, based on testing of over 15,000 samples in 30 disease areas, and
reduced to practice.

In addition to stratifying patients with respect to anticipated clinical
outcomes, EpiSwitch® data offer insights into systems biology and the
physiological manifestation of disease that are beyond the scope of other
molecular modalities. The technology has performed well in academic medical
research settings and has been validated through its integration in biomarker
discovery and clinical development with big pharma.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABELLFZELFBBQ